GDBY new blood testing service is now gaining traction! Read a quick update by our credible analysts on $GDBY:
1. Its Q3 revenue was down 62% YoY, 16% QoQ, beating our analyst's estimate by 14%. EPS was 6% higher than estimates.
2. GDBY conducted 25k tests in Q3, down 17% QoQ. Although segmented results were not disclosed, our analysts believe that the company's new blood testing services have started gaining traction.
3. Company was able to lower G&A expenses by 22% QoQ in Q3, by cutting staff and professional expenses.
Find out if our analysts are raising or lowering their GDBY revenue forecasts for 2023 here: https://www.researchfrc.com/goodbody-health-limited-otcqb-gdbyf-aqse-gdby-gaining-traction-for-new-services/?utm_source=ceo.ca&utm_medium=Referral&utm_campaign=ceo.ca&utm_id=GoodBody+Health
Question of the day: A lot of people were investing in the healthcare sector during COVID. Do you think it's a good bet? Let us know in the comments down below!
*FRC provides issuer-paid coverage.
*Past performance is not indicative of future results.